Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

Susan O’Brien(The University of Texas MD Anderson Cancer Center), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Jeffrey J. Tarrand, Xuelin Huang(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), William G. Wierda(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Todd Riehl, Brandi O’Neal(Leukemia Research Foundation)
Blood
November 27, 2007
10.1182/blood-2007-03-080010
Cited by 89

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k